La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Kyowa Kirin Performance dei guadagni passati

Il passato criteri di controllo 5/6

Kyowa Kirin ha registrato una crescita degli utili a un tasso medio annuo di 15%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 5.4%. I ricavi sono stati in crescita a un tasso medio annuo di 8.2%. Il ritorno sul capitale proprio di Kyowa Kirin è 11.3% e ha margini netti di 20.4%.

Informazioni chiave

15.0%

Tasso di crescita degli utili

15.1%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	3.4%
Tasso di crescita dei ricavi	8.2%
Rendimento del capitale proprio	11.3%
Margine netto	20.4%
Prossimo aggiornamento sui guadagni	31 Oct 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 03

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

May 09

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Apr 25

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Apr 11

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Mar 19

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Feb 27

Ripartizione dei ricavi e delle spese

Come Kyowa Kirin guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

TSE:4151 Ricavi, spese e utili (JPY Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	475,998	97,319	163,879	87,697
31 Mar 24	454,267	83,060	161,463	78,803
31 Dec 23	442,233	81,188	163,078	72,106
30 Sep 23	420,649	57,915	158,138	69,927
30 Jun 23	412,309	40,202	162,077	68,639
31 Mar 23	404,155	50,295	161,796	65,906
31 Dec 22	398,371	53,573	166,185	62,896
30 Sep 22	382,052	68,651	148,265	61,591
30 Jun 22	372,496	62,292	144,307	59,093
31 Mar 22	358,882	55,464	139,539	59,095
31 Dec 21	352,246	52,347	135,105	57,679
30 Sep 21	338,317	42,446	132,495	55,518
30 Jun 21	325,554	44,301	125,537	54,739
31 Mar 21	322,174	46,106	118,474	52,705
31 Dec 20	318,352	47,027	116,525	52,312
30 Sep 20	314,367	48,255	110,498	52,674
30 Jun 20	312,223	46,819	109,172	52,702
31 Mar 20	307,278	42,212	109,275	53,393
31 Dec 19	305,820	37,674	106,245	53,511
30 Sep 19	374,267	38,519	121,871	54,203
30 Jun 19	325,827	38,796	107,909	50,395
31 Mar 19	337,645	41,713	108,972	49,594
31 Dec 18	346,531	54,414	110,283	48,591
30 Sep 18	292,662	65,953	95,512	45,242
30 Jun 18	349,815	63,500	108,093	47,611
31 Mar 18	347,166	56,420	106,321	48,301
31 Dec 17	353,380	42,899	104,608	49,155
30 Sep 17	343,697	21,949	101,407	51,146
30 Jun 17	344,648	21,576	100,090	51,138
31 Mar 17	345,485	19,754	100,666	51,855
31 Dec 16	343,019	18,669	100,621	53,792
30 Sep 16	349,134	20,199	103,038	54,156
30 Jun 16	359,535	31,014	104,852	54,670
31 Mar 16	363,187	32,566	104,818	53,096
31 Dec 15	364,316	29,774	105,702	51,518
30 Sep 15	367,453	29,906	104,174	51,343
30 Jun 15	350,384	16,236	103,163	49,892
31 Mar 15	336,965	14,173	101,054	49,442
31 Dec 14	333,446	15,898	99,396	47,667
30 Sep 14	327,444	18,791	100,050	45,405
30 Jun 14	332,803	21,585	98,603	44,541
31 Mar 14	340,090	26,010	85,674	53,986
31 Dec 13	340,611	30,078	98,037	43,633
30 Sep 13	340,570	32,082	97,370	41,873

Guadagni di qualità: 4151 ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di 4151 (20.4%) 4151 sono più alti rispetto allo scorso anno (9.8%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di 4151 sono cresciuti del 15% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di 4151 nell'ultimo anno ( 142.1% ) supera la media quinquennale ( 15% all'anno).

Guadagni vs Settore: La crescita degli utili 4151 nell'ultimo anno ( 142.1% ) ha superato la percentuale del settore Pharmaceuticals 8.6%.

Kyowa Kirin Performance dei guadagni passati

Il passato criteri di controllo 5/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2024 Results on Feb 06, 2025

First quarter 2024 earnings: EPS misses analyst expectations

Kyowa Kirin Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

Recent updates

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Updates Earnings Guidance for He Fiscal Year 2024

Here's Why Kyowa Kirin (TSE:4151) Has Caught The Eye Of Investors

Kyowa Kirin Co., Ltd.'s (TSE:4151) Share Price Could Signal Some Risk

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2024 Results on Feb 06, 2025

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Final dividend of JP¥29.00 announced

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024

Kyowa Kirin Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

Upcoming dividend of JP¥27.00 per share at 2.3% yield

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

Kyowa Kirin Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Earnings quality

New minor risk - Profit margin trend

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥27.00 per share at 2.0% yield

Kyowa Kirin Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2023

High number of new directors

Full year 2022 earnings: EPS misses analyst expectations

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2022, Payable on March 27, 2023; Provides Dividend Guidance for the Second Quarter of 2023

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2022 Results on Feb 07, 2023

Upcoming dividend of JP¥24.00 per share

Consensus forecasts updated

Kyowa Kirin Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2022

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2022

Kyowa Kirin Co., Ltd. Receives European Commission Approval for Use of CRYSVITA(R) (burosumab) for the Treatment of Tumour-Induced Osteomalacia

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Announces Second Quarter End Dividend for the Fiscal Year Ending December 31, 2022, Payable from September 1, 2022; Provided Year End Dividend Guidance for the Fiscal Year Ending December 31, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

Upcoming dividend of JP¥24.00 per share

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending December 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

High number of new directors

Now 20% undervalued after recent price drop

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 25, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥23.00 per share

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma